Literature DB >> 19042206

Comorbid psychiatric and substance abuse disorders: recent treatment research.

Paula Riggs1, Frances Levin, Alan I Green, Frank Vocci.   

Abstract

Psychiatric comorbidity is defined as the co-occurrence of a psychiatric disorder in a patient with a substance use disorder. Psychiatric disorders in substance abuse patients can antedate the substance use disorder or be a consequence of the substance abuse. There is emerging evidence that drug use in adolescence may alter the onset of certain psychiatric disorders in vulnerable individuals. Patients with concurrent comorbid disorders present special challenges for the substance abuse treatment system in terms of diagnosis and management because each disorder has the capability of exacerbating the other. This manuscript is a summary of an ISAM symposium that featured three speakers who discussed the following topics: 1. Etiology and treatment of comorbid psychiatric and substance use disorders in adolescents; 2. Treatment of ADHD and substance use disorders in adults; 3. Effects of substance abuse on the onset, severity, and treatment of schizophrenia. Recommendations for further research will be presented.

Entities:  

Mesh:

Year:  2008        PMID: 19042206     DOI: 10.1080/08897070802218794

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  10 in total

1.  The Impact of Motivational Interviewing on Delinquent Behaviors in Incarcerated Adolescents.

Authors:  Mary Clair-Michaud; Rosemarie A Martin; Linda A R Stein; Shayna Bassett; Rebecca Lebeau; Charles Golembeske
Journal:  J Subst Abuse Treat       Date:  2015-09-25

2.  Reductions in anxiety and depression symptoms in youth receiving substance use treatment.

Authors:  Viviana E Horigian; Carl F Weems; Michael S Robbins; Daniel J Feaster; Jessica Ucha; Michael Miller; Robert Werstlein
Journal:  Am J Addict       Date:  2013 Jul-Aug

3.  Antipsychotic treatment of adolescent dual diagnosis patients.

Authors:  Scott A Price; Nancy C Brahm
Journal:  J Pediatr Pharmacol Ther       Date:  2011-10

4.  Do executive function deficits predict later substance use disorders among adolescents and young adults?

Authors:  Timothy E Wilens; MaryKate Martelon; Ronna Fried; Carter Petty; Clancey Bateman; Joseph Biederman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-01-06       Impact factor: 8.829

5.  A comparison of treatment outcomes for adolescent community reinforcement approach participants with and without co-occurring problems.

Authors:  Susan H Godley; Brooke D Hunter; Sergio Fernández-Artamendi; Jane Ellen Smith; Robert J Meyers; Mark D Godley
Journal:  J Subst Abuse Treat       Date:  2013-11-11

6.  Screening for substance use disorders in neurodevelopmental disorders: a clinical routine?

Authors:  Margita Palmqvist; Gunnar Edman; Sven Bölte
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-08-15       Impact factor: 4.785

Review 7.  Drug abuse in athletes.

Authors:  Claudia L Reardon; Shane Creado
Journal:  Subst Abuse Rehabil       Date:  2014-08-14

Review 8.  Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.

Authors:  Xanthe M Barkla; Paul A McArdle; Dorothy Newbury-Birch
Journal:  BMC Psychiatry       Date:  2015-10-30       Impact factor: 3.630

9.  Difference in long-term relapse rates between youths with ketamine use and those with stimulants use.

Authors:  Liang-Jen Wang; Mei-Yen Chen; Chin-Yin Lin; Mian-Yoon Chong; Wen-Jiun Chou; Yu-Han You; Chih-Pu Tsai; Yi-Syuan Chen; Shing-Fang Lu
Journal:  Subst Abuse Treat Prev Policy       Date:  2018-12-22

10.  A family-oriented therapy program for youths with substance abuse: long-term outcomes related to relapse and academic or social status.

Authors:  Liang-Jen Wang; Shing-Fang Lu; Mian-Yoon Chong; Wen-Jiun Chou; Yu-Lian Hsieh; Tung-Ning Tsai; Ching Chen; Yi-Hsuan Lee
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-30       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.